Zobrazeno 1 - 10
of 78
pro vyhledávání: '"N. Delev"'
Autor:
S Banerjee, V Shah, M Harrison, Y Shen, JT Merrill, U Ranganathan, MK Crow, N Delev, D Grasela, E Culotta, S Greenberg
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/eefef4ed89c24f87916fc3e1263f4375
Autor:
S Banerjee, S Singhal, V Shah, R Van Vollenhoven, M Pike, E Morand, I Catlett, VP Werth, JT Merrill, N Delev, C Hobar, B Sharkey, T Wegman
Publikováno v:
Lupus Science and Medicine, Vol 9, Iss Suppl 2 (2022)
Externí odkaz:
https://doaj.org/article/7202d674bb32434b9924687621ef56bc
Autor:
R Van Vollenhoven, M Pike, JT Merrill, E Morand, VP Werth, C Hobar, N Delev, V Shah, B Sharkey, T Wegman, I Catlett, S Banerjee, S Singhal
Publikováno v:
Thursday 06 October 2022 from 15:40 to 17:10.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d5f2838268fc77f0d1c3165cb977da2
https://doi.org/10.1136/lupus-2022-elm2022.23
https://doi.org/10.1136/lupus-2022-elm2022.23
Autor:
U Ranganathan, JT Merrill, MK Crow, N Delev, S Banerjee, D Grasela, M Harrison, Y Shen, E Culotta, S Greenberg, V Shah
Publikováno v:
Friday 07 October 2022 from 13:00 to 14:10.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6a09cae9875c16b8ca08978115eadfe0
https://doi.org/10.1136/lupus-2022-elm2022.153
https://doi.org/10.1136/lupus-2022-elm2022.153
Apremilast monotherapy for long-term treatment of active psoriatic arthritis in DMARD-naïve patients
Autor:
Benoit Guerette, N. Delev, Maria Paris, Jacob A. Aelion, Paul Bird, Alvin F. Wells, Alan Kivitz, Christopher J Edwards, L. Teng
Publikováno v:
Rheumatology. 61:1035-1043
Objectives Apremilast monotherapy was evaluated up to 5 years in PALACE 4 (fourth PsA Long-term Assessment of Clinical Efficacy study) DMARD-naïve patients with PsA. Methods Patients with active PsA were randomized (1:1:1) to placebo, apremilast 30
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b460d96bf078d84046186c3a8599934
https://doi.org/10.1093/rheumatology/keab449
https://doi.org/10.1093/rheumatology/keab449
Autor:
Juan J. Gomez-Reino, Stephen Hall, Philip J. Mease, Georg Schett, N. Delev, Dafna D. Gladman, L. Teng, Eric Lespessailles, Jürgen Wollenhaupt, Maria Paris, Arthur Kavanaugh
Publikováno v:
ACR Open Rheumatology, Vol 2, Iss 8, Pp 459-470 (2020)
ACR Open Rheumatology
ACR Open Rheumatology, 2020, ⟨10.1002/acr2.11156⟩
ACR Open Rheumatology
ACR Open Rheumatology, 2020, ⟨10.1002/acr2.11156⟩
OBJECTIVE Psoriatic arthritis (PsA) requires long-term treatment, yet safety concerns and monitoring requirements make maintenance a challenge. This analysis of pooled Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) 1, 2, and 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af41e432a10f189798b6e0b38a4874d5
https://doaj.org/article/fa93086f13fa47d6bce83b4a9731f08f
https://doaj.org/article/fa93086f13fa47d6bce83b4a9731f08f
Autor:
E. Morand, M. Pike, J. T. Merrill, R. Van Vollenhoven, V. P. Werth, C. Hobar, N. Delev, V. Shah, B. Sharkey, T. Wegman, I. Catlett, S. Banerjee, S. Singhal
Publikováno v:
Annals of the Rheumatic Diseases. 81:209-209
BackgroundTyrosine kinase 2 (TYK2) mediates signaling of Type I interferons, IL-23, and IL-12, key cytokines involved in lupus pathogenesis. Deucravacitinib (DEUC) is an oral, selective, allosteric TYK2 inhibitor with a unique mechanism of action, di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86576d747eb3ed8502b3432387fc8db9
https://doi.org/10.1136/annrheumdis-2022-eular.5020a
https://doi.org/10.1136/annrheumdis-2022-eular.5020a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Thomas Dörner, Victoria P. Werth, R. Van Vollenhoven, N. Delev, M. Stern, S. Korish, Peter E. Lipsky, S. Tang, M. Weiswasser, P. Schafer, Richard Furie, Joan T. Merrill, Z. Liu
Publikováno v:
Annals of the Rheumatic Diseases. 80:76-77
Background:Iberdomide is a high-affinity cereblon ligand that promotes proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors involved in innate and adaptive immune cell development and homeostasis, and linked to the gene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6122a1792ac4be06a3ed94ef63a3f060
https://doi.org/10.1136/annrheumdis-2021-eular.2181
https://doi.org/10.1136/annrheumdis-2021-eular.2181
Autor:
Jessica A. Walsh, L. Teng, Peter Nash, Kamal Ohson, Maria Paris, Jacob A. Aelion, N. Delev, Juan J. Gomez-Reino, D. Nguyen
Publikováno v:
Psoriatic arthritis.
Background ACTIVE is the first apremilast (APR) study to demonstrate onset of response to APR starting at Week 2 in biologic-naive subjects with psoriatic arthritis (PsA) who may have had exposure to 1 prior conventional disease-modifying anti-rheuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::070d95e7c5e3d087573b4a77874538ff
https://doi.org/10.1136/annrheumdis-2018-eular.2720
https://doi.org/10.1136/annrheumdis-2018-eular.2720